Cargando…

Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway

Chronic myelogenous leukemia (CML) is a common hematological malignancy. Some patients progressing to the blast phase develop chemotherapeutic drug resistance. In the authors' previous study, it was found that the mammalian target of rapamycin (mTOR) pathway was activated in CML and that rapamy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jie, Liu, Wenjing, Hao, Hongling, Wang, Qiuyi, Xue, Liying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676723/ https://www.ncbi.nlm.nih.gov/pubmed/31404320 http://dx.doi.org/10.3892/ol.2019.10589

Ejemplares similares

Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells
por: Li, Jie, et al.
Publicado: (2021)

PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway
por: Cheng, Zhi Y, et al.
Publicado: (2008)

Tuberostemonine reverses multidrug resistance in chronic myelogenous leukemia cells K562/ADR
por: Wang, Yu Jia, et al.
Publicado: (2017)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022)

Calcitonin receptor gene expression in K562 chronic myelogenous leukemic cells
por: Mould, Richard, et al.
Publicado: (2003)

Lapatinib Induces Autophagy, Apoptosis and Megakaryocytic Differentiation in Chronic Myelogenous Leukemia K562 Cells
por: Huang, Huey-Lan, et al.
Publicado: (2011)

Prodigiosin induced the caspase-dependent apoptosis in human chronic myelogenous leukemia K562 cell
por: Niakani, Maryam, et al.
Publicado: (2020)

Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells
por: Shi, Dan, et al.
Publicado: (2016)

Curcumin and Curcumin-Loaded Nanogel Induce Apoptosis Activity in K562 Chronic Myelogenous Leukemia Cells
por: Khatamsaz, Sepideh, et al.
Publicado: (2018)

Polyamine analog TBP inhibits proliferation of human K562 chronic myelogenous leukemia cells by induced apoptosis
por: WANG, QING, et al.
Publicado: (2015)

Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells
por: Honma, Yoshio, et al.
Publicado: (1990)

Human Platelets Effectively Kill K‐562 Cells, a Chronic Myelogenic Leukemia Cell Line, in vitro
por: Sagawa, Terutaka, et al.
Publicado: (1990)

Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia
por: Guo, Naxin, et al.
Publicado: (2019)

Antitumor Activity and Mechanism of Action of the Antimicrobial Peptide AMP-17 on Human Leukemia K562 Cells
por: Tian, Zhuqing, et al.
Publicado: (2022)

Thymoquinone Inhibits JAK/STAT and PI3K/Akt/ mTOR Signaling Pathways in MV4-11 and K562 Myeloid Leukemia Cells
por: Al-Rawashde, Futoon Abedrabbu, et al.
Publicado: (2022)

Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.
por: Millot, J. M., et al.
Publicado: (1989)

Cytotoxic effects of the compound cis-tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells
por: Pereira, Flávia de Castro, et al.
Publicado: (2014)

Effect of bovine dialyzable leukocyte extract on induction of cell differentiation and death in K562 human chronic myelogenous leukemia cells
por: Sierra-Rivera, Crystel A., et al.
Publicado: (2016)

Genomic amplification of chromosome 7 in the Doxorubicin resistant K562 cell line
por: Ibrahim, Sara.M, et al.
Publicado: (2018)

Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
por: Wang, Wenjing, et al.
Publicado: (2019)

Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell Carcinoma
por: Lu, Zhaoming, et al.
Publicado: (2016)

Corrigendum to “Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis”
por: Wang, Wenjing, et al.
Publicado: (2021)

PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
por: Babichev, Yael, et al.
Publicado: (2016)

Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562
por: Sargent, J M, et al.
Publicado: (2001)

Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin
por: Ni, Fan, et al.
Publicado: (2018)

C(5) modified uracil derivatives showing antiproliferative and erythroid differentiation inducing activities on human chronic myelogenous leukemia K562 cells
por: Brognara, Eleonora, et al.
Publicado: (2011)

Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.
por: Lee, J. T., et al.
Publicado: (1996)

Megakaryocytic differentiation in human chronic myelogenous leukemia K562 cells induced by ionizing radiation in combination with phorbol 12-myristate 13-acetate
por: Hirose, Katsumi, et al.
Publicado: (2013)

Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer
por: Heinonen, Henna, et al.
Publicado: (2008)

In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458
por: Albawardi, Alia, et al.
Publicado: (2014)

Apoptosis Activation in Thyroid Cancer Cells by Jatrorrhizine-Platinum(II) Complex via Downregulation of PI3K/AKT/Mammalian Target of Rapamycin (mTOR) Pathway
por: Lu, KeBin, et al.
Publicado: (2020)

Rapamycin Attenuated Zinc-Induced Tau Phosphorylation and Oxidative Stress in Rats: Involvement of Dual mTOR/p70S6K and Nrf2/HO-1 Pathways
por: Lai, Chencen, et al.
Publicado: (2022)

Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer
por: Liu, Tao, et al.
Publicado: (2021)

PSMD7 downregulation induces apoptosis and suppresses tumorigenesis of esophageal squamous cell carcinoma via the mTOR/p70S6K pathway
por: Shi, Ke, et al.
Publicado: (2018)

Downregulation of PI3K/AKT/mTOR Pathway in Juglone-Treated Bovine Oocytes
por: El-Sheikh, Marwa, et al.
Publicado: (2023)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
por: Murray, James T., et al.
Publicado: (2018)

Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor
por: Artoni, Filippo, et al.
Publicado: (2023)

Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells
por: KANG, QINGWEI, et al.
Publicado: (2015)

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
por: Xin, Pengliang, et al.
Publicado: (2017)

Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells
por: Al-Rawashde, Futoon Abedrabbu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0hvqfj0fgh4ib62rtjf3kqm8fi